Table 1 Demographic and clinical characteristics of patients with refractory Behcet uveitis
From: Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
Age-range at onset (years) | 20–30 | 40–50 | 20–30 | 30–40 | 30–40 |
Duration of IFNα2a treatment (months) | 6 | 5 | 28 | 12 | 2 |
Overall follow-up period (months) | 51 | 27 | 34 | 72 | 110 |
Laterality | Bilateral | Unilateral | Bilateral | Bilateral | Bilateral |
Anatomic classification of uveitis | Panuveitis | Panuveitis | Panuveitis | Panuveitis | Panuveitis |
Extraocular manifestations of BD | Oral ulcer CNS involvement Epididymitis Arthritis Skin lesion (EN) | Oral ulcer Genital ulcer Skin lesion(EN) GI involvement | Oral ulcer Skin lesion (folliculitis) GI involvement | Oral ulcer Skin lesion (EN) | Oral ulcer Skin lesion(EN) |
Previous immunosuppressive treatment | Azathioprine 100 mg/d, Methotrexate 17.5 mg weekly | Cyclosporine 200 mg/d Azathioprine 100 mg/d, Methotrexate 17.5 mg weekly | Cyclosporine 200 mg/d, Azathioprine 100 mg/d | Mycophenolate mofetil 2 g/d | Mycophenolate mofetil 2 g/d |
Dose of oral corticosteroid (mg/d prednisolone equivalent), preTx→postTx | 40 → 10 | 15 → 0 | 20 → 0 | 40 → 5 | 15 → 0 |
Relapse rate (number of uveitis attacks/year), preTx→postTx | 2.13 → 2 | 1.64 → 0 | 4.00 → 0 | 1.80 → 0 | 1.22 → 0 |
Response to IFNα2a | No | Yes | Yes | Yes | Yes |
Adverse events | Flu-like Sx Depression | Flu-like Sx | Flu-like Sx | Flu-like Sx | Flu-like Sx |